News

In October 2023, Hunan Morning Shine Co., Ltd. (hereinafter referred to as "Morning Shine ") announced the successful completion of a Series A financing of over 100 million RMB. This round of financing was led by YuanBio Venture Capital, with SUNZ FUND and Jinyu Maowu participating as follow-on investors. The funds raised will be used to strengthen the company's R&D and production capacity building, accelerate the development of new products, expand into overseas markets, and comprehensively accelerate the company's growth.

In the biopharmaceutical industry, laboratory capabilities serve as a core benchmark for measuring a company’s technical strength. Driven by an unwavering commitment to technical compliance and innovative excellence,Changsha Morning Shine Co., Ltd. first obtained laboratory accreditation from the China National Accreditation Service for Conformity Assessment (CNAS) in May 2022. In July 2023, the company successfully completed site change and scope expansion reviews, adding critical testing capabilities such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry. This accreditation not only signifies that its laboratory management system meets international standards but also represents a major milestone in addressing cutting-edge technical challenges in the industry, injecting strong momentum into the company’s growth.